Testing effectiveness (Phase 2)Study completedNCT03744676
What this trial is testing
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Who this might be right for
Lymphoma, Non-HodgkinLymphomaLymphoma, B-Cell+7 more
Juno Therapeutics, a Subsidiary of Celgene 104